This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Klepstad, P. Search for Related Content PubMed PubMed Citation Articles by Klepstad, P. Social Bookmarking                         What's this?

Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network

Department of Circulation and Medical Imaging, Norwegian University of Science and Technology

Stein Kaasa

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

Nathan Cherny

Pain and Palliative Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

Geoffrey Hanks

Department of Palliative Medicine, Bristol Oncology Centre, Bristol, UK

Franco de Conno

Istituto Nazionale dei Tumori, Milan, Italy

Research Steering Committee of the EAPC

The Research Network of the European Association for Palliative Care (EAPC) performed a survey of 3030 cancer patients from 143 palliative care centres in 21 European countries. The survey addressed pain intensity and the use of non-opioid analgesics, adjuvant analgesics and opioids.

Patients were treated with analgesics corresponding to the WHO pain ladder step I (n / 855), step II (n / 509) and step III (n / 1589). The investigators assessed 32% of the patients as having moderate or severe pain. In general there were small differences between pain intensities across different countries. Cancer primary sites and the presence of metastasis had only minor influences on pain intensity. The most frequently used nonopioid analgesics were NSAIDs (26%) and paracetamol (23%). Adjuvant analgesics or coanalgesics used by / 1% of the patients were corticosteroids (39%), tricylic antidepressants (11%), gabapentin (5%), bisphosphonates (4%), clonazepam (2%), carbamazepine (4%) and phenytoin (2%). The use of non-opioid analgesics and co-analgesics varied widely between countries. Opioids administered for mild to moderate pain were codeine (8%), tramadol (8%), dextropropoxyphene (5%) and dihydrocodeine (2%). Morphine was the most frequently used opioid for moderate to severe pain (oral normal release morphine: 21%; oral sustained-release morphine: 19%; iv or sc morphine: 10%). Other opioids for moderate to severe pain were transdermal fentanyl (14%), oxycodone (4%), methadone (2%), diamorphine (2%) and hydromorphone (1%). We observed large variations in the use of opioids across countries. Finally, we observed that only a minority of the patients who used morphine needed very high doses.

Key Words: analgesics • cancer • opioid • pain • palliative care • survey

Palliative Medicine, Vol. 19, No. 6, 477-484 (2005)
DOI: 10.1191/0269216305pm1054oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F De Conno, C Ripamonti, E Fagnoni, C Brunelli, M Luzzani, M Maltoni, E Arcuri, O Bertetto, and on behalf of MERITO Study Group The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain Palliative Medicine, April 1, 2008; 22(3): 214 - 221. [Abstract] [PDF]